Comparable outcomes of haploidentical, ...
Type de document :
Article dans une revue scientifique
DOI :
PMID :
URL permanente :
Titre :
Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
Auteur(s) :
Lorentino, Francesca [Auteur]
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Centre de Recherche Saint-Antoine [UMRS893]
Bernardi, Massimo [Auteur]
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Ciceri, Fabio [Auteur]
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Socie, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Cornelissen Jan, J [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Esteve, Jordi [Auteur]
Institut d'Investigacions Biomèdiques August Pi i Sunyer [IDIBAPS]
Ruggeri, Annalisa [Auteur]
IRCCS Ospedale Pediatrico Bambino Gesù = Bambino Gesù Children’s Hospital
Volin, Liisa [Auteur]
Helsinki University Hospital [Finland] [HUS]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Craddock, Charles [Auteur]
University of Birmingham [Birmingham]
Passweg, Jakob [Auteur]
University Hospital Basel [Basel]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Poiani, Monica [Auteur]
Fegueux, Nathalie [Auteur]
Hôpital Lapeyronie [Montpellier] [CHU]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Centre de Recherche Saint-Antoine [UMRS893]
Nagler, Arnon [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Labopin, Myriam [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Centre de Recherche Saint-Antoine [UMRS893]
Bernardi, Massimo [Auteur]
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Ciceri, Fabio [Auteur]
IRCCS San Raffaele Scientific Institute [Milan, Italie]
Socie, Gerard [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Cornelissen Jan, J [Auteur]
Erasmus University Medical Center [Rotterdam] [Erasmus MC]
Esteve, Jordi [Auteur]
Institut d'Investigacions Biomèdiques August Pi i Sunyer [IDIBAPS]
Ruggeri, Annalisa [Auteur]
IRCCS Ospedale Pediatrico Bambino Gesù = Bambino Gesù Children’s Hospital
Volin, Liisa [Auteur]
Helsinki University Hospital [Finland] [HUS]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Craddock, Charles [Auteur]
University of Birmingham [Birmingham]
Passweg, Jakob [Auteur]
University Hospital Basel [Basel]
Blaise, Didier [Auteur]
Institut Paoli-Calmettes [IPC]
Gedde-Dahl, Tobias [Auteur]
Oslo University Hospital [Oslo]
Poiani, Monica [Auteur]
Fegueux, Nathalie [Auteur]
Hôpital Lapeyronie [Montpellier] [CHU]
Mohty, Mohamad [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Centre de Recherche Saint-Antoine [UMRS893]
Nagler, Arnon [Auteur]
Université Pierre et Marie Curie - Paris 6 [UPMC]
Titre de la revue :
American Journal of Hematology
Nom court de la revue :
Am. J. Hematol.
Numéro :
93
Pagination :
1236-1244
Date de publication :
2018-07-30
ISSN :
1096-8652
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the ...
Lire la suite >Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the absence of a matched related donor, potential alternatives include 10/10, 9/10 HLA-matched unrelated (UD) or haploidentical (Haplo) donors. We analyzed clinical outcomes of patients undergoing T-cell repleted Haplo (n = 74), 10/10 UD (n = 433) and 9/10 UD HSCT (n = 123) from 2007 to 2015, reported to the EBMT Registry. Adverse risk AML was defined according to the 2017 ELN cytogenetic risk classification. The 2-year nonrelapse mortality was 19% for Haplo, 18% for 10/10 UD and 18% for 9/10 UD (P = .9). The relapse incidence was not significantly affected by donor source, with a 2-year incidence of 27% for Haplo HSCT, 39% for 10/10 UD and 37% for 9/10 UD SCT (P = .3). We show comparable probabilities of leukemia-free survival (LFS) and overall survival (OS) at 2 years among Haplo HSCT, 10/10 UD SCT and 9/10 UD SCT (53% and 59%, 43% and 50%, 44% and 50%, respectively, P = .5 for both parameters). The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable Cox model, Haplo HSCT recipients experienced comparable OS and LFS to 10/10 and 9/10 UD. In the present series of adverse cytogenetics AML patients in CR1, Haplo HSCT recipients had comparable outcomes to those of 10/10 and 9/10 UDs, suggesting that all these types of HSCT may be considered a valid option in this high risk population.Lire moins >
Lire la suite >Allogeneic hematopoietic stem cell transplantation (HSCT) is the most powerful therapy preventing relapse in patients with adverse cytogenetics acute myeloid leukemia (AML) in first complete remission (CR1). In the absence of a matched related donor, potential alternatives include 10/10, 9/10 HLA-matched unrelated (UD) or haploidentical (Haplo) donors. We analyzed clinical outcomes of patients undergoing T-cell repleted Haplo (n = 74), 10/10 UD (n = 433) and 9/10 UD HSCT (n = 123) from 2007 to 2015, reported to the EBMT Registry. Adverse risk AML was defined according to the 2017 ELN cytogenetic risk classification. The 2-year nonrelapse mortality was 19% for Haplo, 18% for 10/10 UD and 18% for 9/10 UD (P = .9). The relapse incidence was not significantly affected by donor source, with a 2-year incidence of 27% for Haplo HSCT, 39% for 10/10 UD and 37% for 9/10 UD SCT (P = .3). We show comparable probabilities of leukemia-free survival (LFS) and overall survival (OS) at 2 years among Haplo HSCT, 10/10 UD SCT and 9/10 UD SCT (53% and 59%, 43% and 50%, 44% and 50%, respectively, P = .5 for both parameters). The type of donor was not significantly associated with either acute or chronic graft-vs.-host disease incidence. Using multivariable Cox model, Haplo HSCT recipients experienced comparable OS and LFS to 10/10 and 9/10 UD. In the present series of adverse cytogenetics AML patients in CR1, Haplo HSCT recipients had comparable outcomes to those of 10/10 and 9/10 UDs, suggesting that all these types of HSCT may be considered a valid option in this high risk population.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Inserm
Université de Lille
CHU Lille
Université de Lille
CHU Lille
Équipe(s) de recherche :
Immunity, inflammation and fibrsis in auto and allo-reactivity
Date de dépôt :
2019-03-01T14:08:03Z
2024-01-19T08:34:42Z
2024-01-19T08:34:42Z